Bristol-Myers Story

<div class='circular--portrait' style='background:#006400;color: #F5FFFA;font-size:4em;'>BS</div>
BMY -- USA Stock  

USD 61.27  1.93  3.25%

Bristol Myers Squibb is scheduled to announce its earnings today. The next earnings report is expected on the 6th of May 2021. Bristol Myers Book Value per Share is fairly stable at the moment as compared to the past year. Bristol Myers reported Book Value per Share of 36.42 in 2020. Dividend Yield is likely to rise to 0.0248 in 2021, whereas Net Income Per Employee is likely to drop slightly above 100.7 K in 2021. As many passive investors are finally getting excited about healthcare space, Bristol Myers Squibb could be a good starting point. We will check if the company can maintain a respectable level of debt while minimizing operating losses.
Published over three weeks ago
View all stories for Bristol-Myers Squibb | View All Stories
What is March outlook for Bristol (NYSE:BMY)?
Bristol Myers Squibb has 45.81 B in debt with debt to equity (D/E) ratio of 0.91, which is OK given its current industry classification. The entity has a current ratio of 1.64, which is typical for the industry and considered as normal. The firm shows a Beta (market volatility) of 0.8857, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Bristol's beta means in this case. Bristol Myers returns are very sensitive to returns on the market. As the market goes up or down, Bristol Myers is expected to follow. Even though it is essential to pay attention to Bristol Myers Squibb historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Bristol Myers Squibb exposes twenty-seven different technical indicators, which can help you to evaluate its performance. Bristol Myers Squibb has an expected return of -0.0488%. Please be advised to confirm Bristol Myers Squibb sortino ratio, as well as the relationship between the semi variance and rate of daily change to decide if Bristol Myers Squibb stock performance from the past will be repeated at some point in the near future.
Bristol-Myers Squibb financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Bristol-Myers Squibb, including all of Bristol-Myers Squibb's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Bristol-Myers Squibb assets, the company is considered highly leveraged. Understanding the composition and structure of overall Bristol-Myers Squibb debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Bristol-Myers Total Debt

Bristol-Myers Squibb liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Bristol-Myers Squibb has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Bristol-Myers Squibb balance sheet include debt obligations and money owed to different Bristol-Myers Squibb vendors, workers, and loan providers. Below is the chart of Bristol-Myers main long-term debt accounts currently reported on its balance sheet.
You can use Bristol-Myers Squibb financial leverage analysis tool to get a better grip on understanding its financial position

How important is Bristol-Myers Squibb's Liquidity

Bristol-Myers Squibb financial leverage refers to using borrowed capital as a funding source to finance Bristol-Myers Squibb ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bristol-Myers Squibb financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bristol-Myers Squibb's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Bristol-Myers Squibb, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Rupert Vessey of 23349 shares of Bristol-Myers Squibb subject to Rule 16b-3

Legal trades by Bristol-Myers Squibb insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bristol-Myers insider trading alert for exercise of restricted stock units by Rupert Vessey, EVP Research & Early Dev., on 3rd of March 2021. This event was filed by Bristol Myers Squibb Co with SEC on 2021-03-03. Statement of changes in beneficial ownership - SEC Form 4. Rupert Vessey currently serves as executive vice president research and early development member of the leadership team of Bristol-Myers Squibb [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down

The firm reported the last year's revenue of 39.4 B. Reported Net Loss for the year was (44 M) with profit before taxes, overhead, and interest of 18.93 B.

Liabilities Breakdown

Tax Liabilities
16.8 B
Current Liabilities
74.4 B
Long-Term Liabilities
Total Liabilities97.09 Billion
Current Liabilities16.81 Billion
Long-Term Liabilities74.38 Billion
Tax Liabilities8.01 Billion

Bristol Myers has 50 percent chance to slide under $63 in the coming weeks

Bristol Myers current coefficient of variation rises over 1429.36. Bristol Myers Squibb has relatively low volatility with skewness of 0.94 and kurtosis of 3.87. However, we advise all investors to independently investigate Bristol Myers Squibb to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Takeaway on Bristol Myers Investment

While some other firms in the drug manufacturers?general industry are either recovering or due for a correction, Bristol Myers may not be performing as strong as the other in terms of long-term growth potentials. With an optimistic outlook on your 30 days horizon, it may be a good time to take in new shares of Bristol or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Bristol Myers.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Bristol-Myers Squibb. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com